Marksans Pharma gets USFDA nod for Acetaminophen ER Tablets
Mumbai: Marksans Pharma Limited today announced that U.S. Food and Drug Administration (USFDA) has granted approval for an Abbreviated New Drug Application (ANDA) for Acetaminophen Extended-Release Tablets USP, 650 mg (OTC).
Acetaminophen Extended-Release Tablets are bioequivalent to the reference listed drug, Tylenol Extended-Release Tablets, 650 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.
"This product approval endorses the capability of Marksans to develop and deliver products on a high barrier platform technology of extended release tablets," the company stated.
Extended release is an advanced technology and is a solution to patient compliance to avoid repeated dosages at short intervals.
Marksans will manufacture the products at its USFDA approved state-of-the-art solid oral dosage facility located at Goa, India.
Read also: Marksans Pharma appoints Dr Meena Rani Surana as Independent Woman Director
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.